<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02484677</url>
  </required_header>
  <id_info>
    <org_study_id>2014-41</org_study_id>
    <secondary_id>2014-005536-34</secondary_id>
    <secondary_id>RCAPHM14_0370</secondary_id>
    <nct_id>NCT02484677</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head &amp; Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy</brief_title>
  <acronym>5-FU</acronym>
  <official_title>Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head &amp; Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) is a mainstay for treating head and neck&#xD;
      cancers, but elderly or fragile patients are often precluded because of the risk of severe&#xD;
      toxicities associated with this protocol. DPD (Dihydro Pyrimidine Dehydrogenase) deficiency&#xD;
      is a pharmacogenetic syndrome responsible for most of the severe/lethal toxicities showing in&#xD;
      5-FU (5-Fluorouracile)-treated patients, and our institute has developed a strategy for the&#xD;
      routine determination of Dihydro Pyrimidine Dehydrogenase (DPD) status prior to starting&#xD;
      giving the 5-FU so as to roughly adapt drug dosage according to the Dihydro Pyrimidine&#xD;
      Dehydrogenase (DPD) status. This project aims at developing a Bayesian strategy to further&#xD;
      individualize 5-FU dosing to reach a target exposure of area under curve (AUC). To this end,&#xD;
      100 patients with head and neck cancer and scheduled for a Docetaxel, Cisplatin,&#xD;
      5-Fluorouracile (=TPF) regimen will be included.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Crop the plasma exposure of 5-FU (5-Fluorouracile) around a predefined target area under the&#xD;
      curve 30 (AUC30) in patients with head and neck cancer treated with Docetaxel, Cisplatin,&#xD;
      5-Fluorouracile (=TPF) protocols and correlate adaptive Bayesian procedure to tolerability.&#xD;
&#xD;
        -  Develop a population die from a group of 20 patients for which a pharmacokinetic study&#xD;
           will be carried out&#xD;
&#xD;
        -  Evaluate obtaining effective concentration of 5-FU in the context of a Docetaxel,&#xD;
           Cisplatin, 5-Fluorouracile (=TPF) protocol adapted by the Bayesian procedure.&#xD;
&#xD;
        -  Compare recommendations in terms of dosage adjustment of Bayesian approach with the&#xD;
           recommendations of a simplified graphical approach.&#xD;
&#xD;
        -  Test the measure of Dihydro Pyrimidine Dehydrogenase (DPD) activity&#xD;
           Dihydrouracil/Uracile (UH2 / U ratio) as a co-variable adjustment of 5-Fluorouracile&#xD;
           (5-FU) regimens in Pharmacogenomics/Pharmacokinetic (PGx / PK) model.&#xD;
&#xD;
        -  Evaluate a prototype of urinary dipsticks for the early detection of toxicity from the&#xD;
           assay as a marker of Dihydro Pyrimidine Dehydrogenase (DPD) activity.&#xD;
&#xD;
        -  Assess the cost-benefit of dosage targeting, in terms of reduction resulting costs to&#xD;
           the management of chemotherapy-induced toxicities.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of 5-FU (5-Fluorouracile)</measure>
    <time_frame>24 months</time_frame>
    <description>Concentration of 5-FU in nanograms per milliliter. Circulating 5-FU will be quantified by immunoassay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicities</measure>
    <time_frame>24 months</time_frame>
    <description>will be graded according to Common toxicity Criteria (CTC) 2.0 standards.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Patients With Head and Neck Cancer (ORL)</condition>
  <arm_group>
    <arm_group_label>Head and neck cancer patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Association of Docetaxel, Cisplatin, 5-Fluorouracile for pharmacokinetic evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation</description>
    <arm_group_label>Head and neck cancer patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Taxanes. Blood sampling for pharmacokinetic evaluation</description>
    <arm_group_label>Head and neck cancer patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracile</intervention_name>
    <description>Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation</description>
    <arm_group_label>Head and neck cancer patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 and â‰¤ 80 years.&#xD;
&#xD;
          -  Squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx,&#xD;
             larynx, nasopharynx).&#xD;
&#xD;
          -  Locally advanced stage (III, IVa or IVb).&#xD;
&#xD;
          -  The patient must have received the information note and signing the informed consent,&#xD;
             as well as being spent in multidisciplinary meeting after which treatment with TPF&#xD;
             (Docetaxel, Cisplatin, 5-Fluorouracile) induction chemotherapy was proposed.&#xD;
&#xD;
          -  Performance Status less than or equal to 2 (WHO performance index).&#xD;
&#xD;
          -  The patient must be affiliated to a social security scheme and followed in one of the&#xD;
             participating centers.&#xD;
&#xD;
          -  Patients polymorphonuclear neutrophil greater than or equal to 1000 / mm3, platelets&#xD;
             greater than or equal to 100 000 / mm3, hemoglobin greater than or equal to 8 g / dl,&#xD;
             transaminases less than or equal to 1.5 times the normal, total bilirubin or equal 1.5&#xD;
             times the normal creatinine clearance in the upper or equal to 50 ml / min&#xD;
             Modification of Diet in Renal Disease (MDRD)&#xD;
&#xD;
          -  Satisfactory heart function&#xD;
&#xD;
          -  Patients must be able to submit to the rhythm of visits, treatment plan, laboratory&#xD;
             balances and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient &gt; 80 years.&#xD;
&#xD;
          -  Patients with uncontrolled infection that could compromise participation in the study.&#xD;
&#xD;
          -  Patients with other serious concomitant diseases and / or uncontrolled that could&#xD;
             compromise participation in the study.&#xD;
&#xD;
          -  Patients with serum bilirubin&gt; under limit normal and / or Alanine Transaminase (ALAT)&#xD;
             and Aspartate Transaminase (AST) 3.5 times the under limit normal with alkaline&#xD;
             phosphatase greater than 6 times the under limit normal.&#xD;
&#xD;
          -  Cardiovascular disease or clinically significant cardiovascular disorder in the&#xD;
             judgment of the investigator, such as, but not limited to uncontrolled hypertension,&#xD;
             congestive heart failure The New York Heart Association (NYHA) classification&gt; III),&#xD;
             unstable angina, myocardial infarction in 6 months prior to treatment, uncontrolled&#xD;
             arrhythmias, chronic liver or renal disease, severely impaired lung function.&#xD;
&#xD;
          -  Disorders significant acute gastrointestinal or recent with a major symptom of&#xD;
             diarrhea, such as Crohn's disease, malabsorption syndrome or diarrhea Common toxicity&#xD;
             Criteria for Adverse Events (CTCAE) grade&gt; 1 whatever aetiology.&#xD;
&#xD;
          -  Performance Status and / or laboratory tests incompatible with chemotherapy using&#xD;
             cisplatin, docetaxel and 5-fluorouracile (5-FU)&#xD;
&#xD;
          -  Inability to submit to medical monitoring test for geographical reasons, family,&#xD;
             social or psychological.&#xD;
&#xD;
          -  Patients refusing to participate in biological assessments.&#xD;
&#xD;
          -  Persons deprived of liberty or guardianship.&#xD;
&#xD;
          -  Pregnant women or likely to be at the time of enrollment or during breastfeeding.&#xD;
&#xD;
          -  Free, informed and signed not obtained.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urielle DESALBRES, Director</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique HÃ´pitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SÃ©bastien SALAS, Professor</last_name>
    <phone>04.91.38.57.08</phone>
    <email>sebastien.salas@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Urielle DESALBRES, Director</last_name>
    <phone>04.91.38.27.47</phone>
    <email>drci@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique HÃ´pitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urielle DESALBRES, Director</last_name>
    </contact>
    <investigator>
      <last_name>Sebastien SALAS, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 22, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

